{"Symbol": "ACLX", "AssetType": "Common Stock", "Name": "Arcellx Inc", "Description": "Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.", "CIK": "1786205", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "800 BRIDGE PARKWAY, REDWOOD CITY, CA, UNITED STATES, 94065", "OfficialSite": "https://www.arcellx.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "3960867000", "EBITDA": "-235726000", "PERatio": "None", "PEGRatio": "None", "BookValue": "7.63", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-3.93", "RevenuePerShareTTM": "0.648", "ProfitMargin": "0", "OperatingMarginTTM": "-12.48", "ReturnOnAssetsTTM": "-0.213", "ReturnOnEquityTTM": "-0.472", "RevenueTTM": "35898000", "GrossProfitTTM": "-132267000", "DilutedEPSTTM": "-3.93", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.81", "AnalystTargetPrice": "110.53", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "15", "AnalystRatingHold": "2", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "110.34", "PriceToBookRatio": "8.99", "EVToRevenue": "98.93", "EVToEBITDA": "-6.52", "Beta": "0.356", "52WeekHigh": "94.07", "52WeekLow": "47.86", "50DayMovingAverage": "67.67", "200DayMovingAverage": "71.88", "SharesOutstanding": "57823000", "SharesFloat": "39458900", "PercentInsiders": "12.914", "PercentInstitutions": "104.836", "DividendDate": "None", "ExDividendDate": "None"}